<?xml version='1.0' encoding='utf-8'?>
<document id="25394092"><sentence text="Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach."><entity charOffset="28-38" id="DDI-PubMed.25394092.s1.e0" text="rifampicin" /><entity charOffset="42-51" id="DDI-PubMed.25394092.s1.e1" text="darunavir" /><entity charOffset="52-61" id="DDI-PubMed.25394092.s1.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25394092.s1.e0" e2="DDI-PubMed.25394092.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s1.e0" e2="DDI-PubMed.25394092.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s1.e0" e2="DDI-PubMed.25394092.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25394092.s1.e1" e2="DDI-PubMed.25394092.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s1.e1" e2="DDI-PubMed.25394092.s1.e2" /></sentence><sentence text="Treatment of HIV/TB co-infection is challenging due to high drug-drug interaction potential between antiretrovirals and rifamycins, such as rifampicin (RIF)"><entity charOffset="120-130" id="DDI-PubMed.25394092.s2.e0" text="rifamycins" /><entity charOffset="140-150" id="DDI-PubMed.25394092.s2.e1" text="rifampicin" /><entity charOffset="152-155" id="DDI-PubMed.25394092.s2.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.25394092.s2.e0" e2="DDI-PubMed.25394092.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s2.e0" e2="DDI-PubMed.25394092.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s2.e0" e2="DDI-PubMed.25394092.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25394092.s2.e1" e2="DDI-PubMed.25394092.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s2.e1" e2="DDI-PubMed.25394092.s2.e2" /></sentence><sentence text=" The PK interaction between darunavir/ritonavir (DRV/RTV) and RIF has not been studied"><entity charOffset="28-37" id="DDI-PubMed.25394092.s3.e0" text="darunavir" /><entity charOffset="38-47" id="DDI-PubMed.25394092.s3.e1" text="ritonavir" /><entity charOffset="62-70" id="DDI-PubMed.25394092.s3.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.25394092.s3.e0" e2="DDI-PubMed.25394092.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s3.e0" e2="DDI-PubMed.25394092.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s3.e0" e2="DDI-PubMed.25394092.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25394092.s3.e1" e2="DDI-PubMed.25394092.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s3.e1" e2="DDI-PubMed.25394092.s3.e2" /></sentence><sentence text=" Utilizing other protease inhibitor data, population PK modelling and simulation was applied to assess the impact of RIF on DRV/RTV PK and generate alternative dosing strategies to aid future clinical trial design"><entity charOffset="117-119" id="DDI-PubMed.25394092.s4.e0" text="RIF" /></sentence><sentence text="" /><sentence text="A previously developed model describing DRV/RTV PK including data from three studies in HIV patients was used [n=51, 7 female, DRV/RTV 800/100 mg (n=32) or 900/100 mg once daily (qd; n=19) (1)" /><sentence text=" The PK interaction between DRV/RTV and RIF was assumed to mimic that observed in HIV-infected, TB negative patients receiving lopinavir (LPV)/RTV (n=21) (2)"><entity charOffset="127-136" id="DDI-PubMed.25394092.s7.e0" text="lopinavir" /><entity charOffset="138-141" id="DDI-PubMed.25394092.s7.e1" text="LPV" /><entity charOffset="40-42" id="DDI-PubMed.25394092.s7.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.25394092.s7.e2" e2="DDI-PubMed.25394092.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25394092.s7.e2" e2="DDI-PubMed.25394092.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s7.e2" e2="DDI-PubMed.25394092.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25394092.s7.e0" e2="DDI-PubMed.25394092.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s7.e0" e2="DDI-PubMed.25394092.s7.e1" /></sentence><sentence text=" Simulations of DRV/RTV 800/100 mg qd (n=1000) were performed (-RIF)"><entity charOffset="64-66" id="DDI-PubMed.25394092.s8.e0" text="RIF" /></sentence><sentence text=" The model was adapted to increase the typical value of apparent oral clearance (CL/F) by 71% and 36% and decrease relative bioavailability (F) by 20% and 45% for DRV and RTV, respectively (2); 1000 simulations were generated (+RIF)"><entity charOffset="228-230" id="DDI-PubMed.25394092.s9.e0" text="RIF" /></sentence><sentence text=" Dose adjustments of DRV/RTV 1200/200 mg qd, 800/100 mg and 1200/150 mg twice daily (bid) were simulated to overcome the interaction" /><sentence text=" DRV trough (Ctrough) for each dosing scenario was compared to the reference (-RIF) by GMR (90% CI)"><entity charOffset="79-81" id="DDI-PubMed.25394092.s11.e0" text="RIF" /></sentence><sentence text="" /><sentence text="DRV and RTV were described by a 1 and 2-compartment model, respectively" /><sentence text=" A maximum effect model, with RTV inhibiting DRV CL/F, best described the relationship between the drugs" /><sentence text=" Compared to the reference (-RIF), simulated DRV Ctrough was 70%, 46% and 20% lower for 800/100 mg qd, 1200/200 mg qd and 800/100 mg bid all +RIF, respectively"><entity charOffset="29-31" id="DDI-PubMed.25394092.s15.e0" text="RIF" /><entity charOffset="142-144" id="DDI-PubMed.25394092.s15.e1" text="RIF" /><pair ddi="false" e1="DDI-PubMed.25394092.s15.e0" e2="DDI-PubMed.25394092.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25394092.s15.e0" e2="DDI-PubMed.25394092.s15.e1" /></sentence><sentence text=" Ctrough was 38% higher with 1200/150 mg bid +RIF (Table 1)"><entity charOffset="46-48" id="DDI-PubMed.25394092.s16.e0" text="RIF" /></sentence><sentence text="" /><sentence text="Modelling and simulation was used to investigate the theoretical impact of RIF on DRV/RTV PK"><entity charOffset="75-77" id="DDI-PubMed.25394092.s18.e0" text="RIF" /></sentence><sentence text=" Based on simulations, 800/100 mg and 1200/150 mg both bid could largely overcome the impact of the interaction" /><sentence text=" However, the risk of increased RTV-related side effects and higher pill burden should be considered" /><sentence text=" In vitro work is ongoing to develop a physiologically based model characterizing the interaction and informing simulations" /><sentence text="" /></document>